FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143201063> ?p ?o ?g. }

• W2143201063 endingPage "70" @default.
• W2143201063 startingPage "66" @default.
• W2143201063 abstract "Erythropoietic agents have transformed the management of renal anaemia. Two forms of recombinant human erythropoietin (rHuEPO) have been available since the early 1990s, and more recently, a second‐generation erythropoietic agent, darbepoetin alfa, has been granted a licence for treating this condition. The endogenous erythropoietin molecule may contain anything from 4 to 14 sialic acid residues. The various isoforms have different biological potencies in vivo owing to their different metabolic clearance rates. However, there is a continuing debate about those organs potentially involved in the metabolism of the erythropoietin molecule; the kidneys, liver, and bone marrow have all been suggested as possible participants. Darbepoetin alfa contains two extra N‐linked glycosylation consensus sequences increasing the potential maximum number of sialic acid residues from 14 up to 22. In vitro, the affinity of darbepoetin alfa for the erythropoietin receptor is less than for the natural ligand, but this is more than compensated for by the increased potency in vivo. One of the most important factors determining the biological activity of erythropoiesis‐stimulating agents is the length of time that the serum concentration of the protein remains above the threshold necessary for erythropoiesis. The pharmacokinetic profile of darbepoetin alfa is distinct from that of rHuEPO, the major difference being the much longer elimination half‐life and slower clearance in vivo of darbepoetin alfa leading to prolonged erythropoietic activity. Stimulation of erythropoiesis depends both on an ambient circulating level of erythropoietin and on the mechanisms governing the interaction of the hormone with its receptor. Our knowledge regarding the latter is limited and it is difficult to predict the optimum frequency of administration for an erythropoietic agent. In general, rHuEPO is given two or three times weekly. A small number of studies have supported the once‐weekly use of rHuEPO. All clinical trials so far conducted on darbepoetin alfa have demonstrated success with once‐weekly and once every other week dosing." @default.
• W2143201063 created "2016-06-24" @default.
• W2143201063 creator A5021273139 @default.
• W2143201063 date "2002-05-01" @default.
• W2143201063 modified "2023-10-16" @default.
• W2143201063 title "Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations" @default.
• W2143201063 cites W170481720 @default.
• W2143201063 cites W1970157737 @default.
• W2143201063 cites W1974191492 @default.
• W2143201063 cites W1976052823 @default.
• W2143201063 cites W1978081881 @default.
• W2143201063 cites W2013563801 @default.
• W2143201063 cites W2039728906 @default.
• W2143201063 cites W2043738725 @default.
• W2143201063 cites W2077030445 @default.
• W2143201063 cites W2078051873 @default.
• W2143201063 cites W2088017842 @default.
• W2143201063 cites W2108511043 @default.
• W2143201063 cites W2112657209 @default.
• W2143201063 cites W2135819931 @default.
• W2143201063 cites W2150897436 @default.
• W2143201063 cites W2155348627 @default.
• W2143201063 cites W2272758509 @default.
• W2143201063 cites W2289738544 @default.
• W2143201063 cites W2292634520 @default.
• W2143201063 cites W2321111200 @default.
• W2143201063 cites W2400547480 @default.
• W2143201063 cites W2403278415 @default.
• W2143201063 cites W2410881390 @default.
• W2143201063 cites W2411226081 @default.
• W2143201063 cites W2417716599 @default.
• W2143201063 cites W2418127509 @default.
• W2143201063 cites W5426360 @default.
• W2143201063 doi "https://doi.org/10.1093/ndt/17.suppl_5.66" @default.
• W2143201063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12091611" @default.
• W2143201063 hasPublicationYear "2002" @default.
• W2143201063 type Work @default.
• W2143201063 sameAs 2143201063 @default.
• W2143201063 citedByCount "111" @default.
• W2143201063 countsByYear W21432010632012 @default.
• W2143201063 countsByYear W21432010632013 @default.
• W2143201063 countsByYear W21432010632014 @default.
• W2143201063 countsByYear W21432010632015 @default.
• W2143201063 countsByYear W21432010632016 @default.
• W2143201063 countsByYear W21432010632017 @default.
• W2143201063 countsByYear W21432010632018 @default.
• W2143201063 countsByYear W21432010632019 @default.
• W2143201063 countsByYear W21432010632020 @default.
• W2143201063 countsByYear W21432010632021 @default.
• W2143201063 countsByYear W21432010632022 @default.
• W2143201063 countsByYear W21432010632023 @default.
• W2143201063 crossrefType "journal-article" @default.
• W2143201063 hasAuthorship W2143201063A5021273139 @default.
• W2143201063 hasBestOaLocation W21432010631 @default.
• W2143201063 hasConcept C111113717 @default.
• W2143201063 hasConcept C112705442 @default.
• W2143201063 hasConcept C126322002 @default.
• W2143201063 hasConcept C134018914 @default.
• W2143201063 hasConcept C150903083 @default.
• W2143201063 hasConcept C207001950 @default.
• W2143201063 hasConcept C2776164570 @default.
• W2143201063 hasConcept C2778248108 @default.
• W2143201063 hasConcept C2778534260 @default.
• W2143201063 hasConcept C2779703530 @default.
• W2143201063 hasConcept C2781404941 @default.
• W2143201063 hasConcept C31102739 @default.
• W2143201063 hasConcept C71924100 @default.
• W2143201063 hasConcept C86803240 @default.
• W2143201063 hasConcept C98274493 @default.
• W2143201063 hasConceptScore W2143201063C111113717 @default.
• W2143201063 hasConceptScore W2143201063C112705442 @default.
• W2143201063 hasConceptScore W2143201063C126322002 @default.
• W2143201063 hasConceptScore W2143201063C134018914 @default.
• W2143201063 hasConceptScore W2143201063C150903083 @default.
• W2143201063 hasConceptScore W2143201063C207001950 @default.
• W2143201063 hasConceptScore W2143201063C2776164570 @default.
• W2143201063 hasConceptScore W2143201063C2778248108 @default.
• W2143201063 hasConceptScore W2143201063C2778534260 @default.
• W2143201063 hasConceptScore W2143201063C2779703530 @default.
• W2143201063 hasConceptScore W2143201063C2781404941 @default.
• W2143201063 hasConceptScore W2143201063C31102739 @default.
• W2143201063 hasConceptScore W2143201063C71924100 @default.
• W2143201063 hasConceptScore W2143201063C86803240 @default.
• W2143201063 hasConceptScore W2143201063C98274493 @default.
• W2143201063 hasIssue "90005" @default.
• W2143201063 hasLocation W21432010631 @default.
• W2143201063 hasLocation W21432010632 @default.
• W2143201063 hasOpenAccess W2143201063 @default.
• W2143201063 hasPrimaryLocation W21432010631 @default.
• W2143201063 hasRelatedWork W1970838504 @default.
• W2143201063 hasRelatedWork W1998587742 @default.
• W2143201063 hasRelatedWork W2007053419 @default.
• W2143201063 hasRelatedWork W2044693699 @default.
• W2143201063 hasRelatedWork W2078636555 @default.
• W2143201063 hasRelatedWork W2143201063 @default.
• W2143201063 hasRelatedWork W2416185362 @default.
• W2143201063 hasRelatedWork W2513328039 @default.
• W2143201063 hasRelatedWork W2943205375 @default.

• next